Background: Hemodialysis patients have frequent infections, especially of the vascular access site, and often harbor antimicro bial-resistant pathogens. Therefore a voluntary national system was created to monitor and prevent infections in these patients.
Infections in patients undergoing hemodialysis have adverse consequences for the individual patient, including increased morbidity and mortali ty, and for society, including increased costs, hospi talization rates, and need for antimicrobials. As a result of their frequent receipt of antimicrobials, particularly vancomycin, antimicrobial resistance has been common in patients undergoing dialysis. One of the first reports of vancomycin-resistant enterococci was from a renal unit in London, England. 3 In the United States, patients undergoing dialysis have comprised a significant percentage of vancomycin-resistant enterococci cases in hospitalbased studies. 4 Also, of 6 US patients from whom strains of Staphylococcus aureus with reduced sus ceptibility to vancomycin have been isolated, 5 had received dialysis. 5 Although systems for monitoring infections in patients who are hospitalized have been in place for many years, 6 uniform methods to study infections in outpatient groups have not been available. In 1999, the Centers for Disease Control and Prevention (CDC) initiated the Dialysis Surveillance Network, a data monitoring system for outpatients undergoing hemodialysis. 7 This is the first report presenting data collected in this system.
METHODS
Dialysis centers treating outpatients undergoing hemodialysis were invited to participate in this proj ect on a voluntary basis. Participating centers agreed to collect data according to the study protocol and participate in a conference call to review the proce dures and data collection process. The study proto col was approved by the Institutional Review Board at the CDC, and by institutional review boards at par ticipating dialysis centers, where applicable. From August 1999 to August 2000, project data were recorded on paper forms by personnel at participat ing centers and forwarded to the CDC for data entry. In September 2000, an Internet-based data entry and analysis system was made available, and thereafter data could be either reported to the CDC on paper forms or entered into a computer at the participating centers. Data tables and analyses were mailed to all participating centers every 3 months. Centers using the Internet-based system could generate and print out analysis tables and graphs whenever desired.
Data collection
Only outpatients receiving chronic hemodialysis were studied. Data were collected on census (denominator) and incident (numerator) forms. Copies of these forms are available at http://www. cdc.gov/ncidod/hip/Dialysis/procedure.htm. The census form was used to record the number of patients undergoing chronic hemodialysis who received hemodialysis at the dialysis center at least once during the first week of the month. The patients were categorized into 1 of 4 vascular access types (fistulas, grafts, cuffed catheters, or noncuffed catheters). If a patient had both an implanted access (fistula or graft) and a catheter, the patient was cat egorized as having a catheter.
An incident form was completed for each overnight hospitalization of any cause or outpatient start of an intravenous (IV) antimicrobial of any cause in a patient undergoing chronic hemodialysis. If a patient was given an antimicrobial and hospitalized on the same day, only one incident form was com pleted. A form was completed for each hospitaliza tion, regardless of how soon after a previous hospi talization it occurred; however, if a patient was receiving an antimicrobial when he or she returned from the hospital to the outpatient unit, a new inci dent form was not completed. If a patient was receiving an antimicrobial and the agent was stopped for <21 days and then restarted, a new incident form was not completed; however, if antimicrobials were stopped for ≥21 days and then restarted, a new incident form was completed.
Data collected on the incident form included the date of the hospitalization or the date when the IV antimi crobial was first given; treated with an IV antimicro bial, researchers noted whether IV vancomycin was used; type of vascular access and if it was removed as a result of the incident; whether clinical evidence for local access infection, wound infection, pneumonia, or urinary tract infection was present (see below); whether a blood culture was obtained, and, if so, the result; and if the blood culture was positive, the source (see below), genus, and species identities of up to 2 organisms and results of susceptibility testing of these organisms to oxacillin and vancomycin.
Clinical evidence for infections was as follows:
• Local access infection: pus, redness, or swelling of the vascular access site • Wound infection: pus or redness at a wound not related to the vascular access • Pneumonia: a new infiltrate or pneumonia seen on chest radiograph • Urinary tract infection: a urine culture with >100,000 organisms/mL with no more than 2 species isolated
The source of a positive blood culture was designat ed as:
• The vascular access if there was access drainage, pus, redness, swelling, pain, an open area, or a positive culture from the access showing the same organism found in the blood • A site other than the vascular access (ie, sec ondary bacteremia) if (1) a culture from another site (eg, leg wound or urine) showed the same organism found in the blood or (2) clinical evi dence of infection at another site, but a culture was not taken from it • A contaminant if the organism was judged to be a contaminant by a physician • Uncertain if there was insufficient evidence to decide among the 3 previous categories.
Definitions
Data on the incident forms were evaluated with a computer algorithm to determine whether each incident met the definitions of one or more of the following events. Note that all definitions included either hospital admission or initiation of an IV antimicrobial in addition to the criteria listed below.
• Local access infection: pus, redness, or swelling of the vascular access site and access-related bacteremia was not present • Positive blood culture: isolation of any microor ganism from a blood culture • Access-related bacteremia: blood culture positive with source the vascular access site or unknown • Vascular access infection: either local access infection or access-related bacteremia • Wound infection: pus or redness at a wound not related to the vascular access • Pneumonia: a new infiltrate or pneumonia seen on chest radiograph • Urinary tract infection: a urine culture with >100,000 organisms/mL with no more than 2 species isolated • Secondary bacteremia: positive blood culture with a source designated as a site other than the vascular access.
Comparison of participating vs nonpartic ipating centers
Data from the National Surveillance of DialysisAssociated Diseases in the United States, 1999, 8 were Tokars, Miller, and Stein used to assess the representativeness of centers par ticipating in the project. This is a yearly mail survey of all US centers providing outpatient hemodialysis.
Data analysis
Data were entered into SQL Server (Microsoft, Redmond, CA) and analyzed with SAS for personal computers (SAS Institute, Cary, NC).* For a given center, the total number of patient-months was cal culated by summing the census during the first week of each month of data collection; for example, a center treating 57, 54, and 59 patients during the first week of 3 successive months would have a total of 170 patient-months for the 3-month period. Rates per 100 patient-months for various outcome events were calculated by dividing the total number of events by the total number of patient-months and multiplying the result by 100; this rate can be inter preted as the average percent of patients having the stated event each month. Rate ratios were computed by dividing the rate in one group by the rate in a sec ond (baseline) group; 95% confidence intervals (CI) for rate ratios were computed with the exact bino mial method, 9 and exact P values were computed with the binomial or Poisson distribution. 10 Rate ratios standardized for mix of vascular access types were calculated with the method of indirect stand ardization. 10 All P values are two-tailed. 
RESULTS

From
Comparison of participating vs nonpartic ipating centers
Data reported in a yearly mail survey of all US dial ysis centers performed in December 1999 showed that, compared with US dialysis centers not partici pating in the project, participating centers were more likely to be nonprofit (58.3% vs 18.3%) and hospital-affiliated (67.6% vs 17.1%) ( Table 1) . Participating centers were similar to nonparticipat ing centers in the number of patients treated (54 vs 56, respectively) but treated a higher percentage of patients with vancomycin during a 1-month period (4.9% vs 4.3%, respectively). In addition, the distri bution of vascular access types was similar for par ticipating vs nonparticipating centers (note that data in Table 1 were taken from the December 1999 mail survey and, therefore, differ from data collected in the data monitoring system and reported elsewhere in this article).
Census
The typical variation in numbers of patients treated each month is illustrated by census data from a rep resentative dialysis center ( Table 2 ). The first month census (57 patients) was 7.9% lower than the cen ter's mean census (61.9 patients). The average vari ation in census at this center was 7.2% per month, higher than the average per month variation for all participating centers (5.8%).
Incidents and event rates
Of 13,705 incidents reported, 10,102 (74%) were for hospitalization only, 2885 (21%) incidents were for the administration of IV antimicrobial only, and 718 (5%) were for both a hospital admission and administering IV antimicrobial. Among 3603 inci dents of IV antimicrobial administration, the pro portion with a blood culture obtained was 60% overall and ranged from 17% to 97% among 51 centers having at least 20 incidents of IV antimi crobial administration.
A total of 2429 vascular access infections were reported; 1292 (53%) of these infections resulted in loss of the access, including the loss of 21 fistu las, 109 grafts, 873 cuffed catheters, and 289 noncuffed catheters. The 2429 vascular access infec tions included 1082 (45%) local access infections and 1347 (55%) access-related bacteremias. Among local access infections, 293 (27%) were treated with hospitalization and 789 (73%) with outpatient IV antimicrobials. In contrast, among access-related bacteremias, 827 (61%) were treat ed with hospitalization and 520 (39%) with outpa tient IV antimicrobials.
Most event rates varied substantially by vascular access type. The hospitalization rate per 100 patientmonths was 14.3 overall, 9.4 for grafts, 12.9 for fistu las, 20.5 for cuffed catheters, and 32.0 for noncuffed catheters ( Among infections not related to the vascular access, rates per 100 patient-months were 1.29 for wound Includes 76 centers with ≥200 patient-months of data. Diagonal fill, rate significantly (P <.05) lower than other centers (n = 11 centers); dotted fill, rate not significantly different from others (n = 51 centers); solid fill, rate significantly higher than others (n = 14 centers). 
Vascular-access infection rates in indi vidual dialysis centers
Among 76 dialysis centers reporting at least 200 patient-months of data, rates of vascular access infection per 100 patient-months varied from 0.31 to 3.98 and rate ratios standardized for differences in mix of vascular access types varied from 0.1 to 2.7 ( Figure 1 ). Of the 76 centers, 11 had a standard ized rate ratio significantly (P <.05) lower than oth ers, 51 were not significantly different from others, 
Microorganisms isolated from blood
Among 1747 positive blood cultures, 1919 isolates were reported. Of the 1919 isolates, 1244 (66%) rep resented access-related bacteremias in patients with catheters; 232 (12%) access-related bacteremias in patients with fistulas or grafts; 363 (19%) secondary bacteremias; and 80 (4%) contaminants. Among isolates from access-related bacteremia in patients with catheters, 32% were S. aureus and 36% were common skin contaminants (predominantly coagu lase-negative staphylococci) ( Table 4) . Among iso lates from access-related bacteremias in patients with fistulas or grafts, 53% were S. aureus.
Among isolates tested for antimicrobial susceptibility, 38% (225 of 558) of S. aureus were resistant to oxacillin, 65% (294 of 449) of coagulase-negative staphylococci were resistant to oxacillin, and 4.6% (7 of 154) of Enterococcus spp were resistant to van comycin.
DISCUSSION
These initial results are from the first national sys tem for monitoring infections and related events in outpatients undergoing hemodialysis. These data represent the largest study ever undertaken of this problem. This project was started as a result of the high rates of infection in these patients, the strong link with antimicrobial resistance, and the lack of uniform methods for data collection. Rates of vari ous events per 100 patient-months are reported, which can be interpreted as the average percentage of patients having the event each month. On aver age, 14% of patients were admitted to a hospital for any cause each month, 4.7% were started on an outpatient course of an IV antimicrobial, and 3.2% had a vascular access infection, 55% of which had accompanying bacteremia.
As has been reported by others, 2 this study indicates that rates of infections and other events were sub stantially higher in patients who underwent dialysis with the use of catheters, especially noncuffed catheters. Catheters are a portal of entry for infec tion and are probably used in patients with higher severity of illness (ie, those who have required dial ysis longer and for whom there are no other options for vascular access). The high infection rates associ ated with catheters are a concern because both the number of patients undergoing hemodialysis and the percentage of patients with dialysis catheters are increasing each year. 8 In most hospital-based studies of bloodstream infections, the numbers of patients with catheters is counted each day and rates of infection per 1000 catheter-days are calculated. 6 However the census is much more stable in outpatient dialysis centers; therefore, in the Dialysis Surveillance Network the census is determined only during the first week of the month. During the remainder of the month, some patients will be added and others removed from the census, but the first-week census should be a good estimate of the average daily census dur ing the month. This method allows calculation of relatively accurate rates while greatly reducing the burden of collecting denominator data. Additionally, the resulting rates have an intuitive interpretation; a vascular access infection rate of 3.2 per 100 patientmonths indicates that, on average, 3.2% of the patients had the infection each month. Rates per 100 patient-months are approximately 3 times higher than rates per 1000 patient-(or catheter-) days; the rate of 3.2 per 100 patient-months is equivalent to a rate of 1.1 per 1000 patient-days.
The rate of vascular access infection (which includes infections both with and without bac teremia) found (3.2 per 100 patient-months) is sim ilar to the rate (3.5 per 100 patient-months) found in a pilot study of the system at 7 dialysis centers, 11 and it is in the range reported in other studies (1.3 7.2 per 100 patient-months). [12] [13] [14] [15] However the reported rate of access-related bacteremia (1.8 per 100 patient-months) was higher than previously reported rates (1.2-1.38 per 100 patient-months). 11, 15 Differences in infection rates among various studies may be a result of differences in study methods and definitions, mix of vascular access types, intrinsic risk of the patients studied, or use of infection con trol measures at study centers.
Blood cultures were performed before only 32% of IV antimicrobial courses in a study of 7 outpatient dialy sis units 11 and only 60% in the surveillance system. The higher rate in the system may result from the selfselection process of the participating centers (ie, vol untarily choose to collect and report data in a quality promotion activity), and a majority are nonprofit hos pital-based units. Therefore the participating units may be more likely to comply with good patient-care practices. Blood cultures should be obtained before most courses of IV antimicrobials in patients under going hemodialysis. The results of such cultures could help optimize antimicrobial use and the duration of treatment so infections could be eradicated while minimizing selection for antimicrobial resistance.
The distribution of bloodstream isolates reported here is similar to that found in previous studies.
Among blood isolates from patients with hemodial ysis catheters, 32% were S. aureus and 32% were coagulase-negative staphylococci; data pooled from other studies showed proportions of 30% and 38%, respectively. 16 Bloodstream isolates from patients with catheters in the intensive care unit showed a similar percentage of coagulase-negative staphylo cocci (33.5%) but a lower percentage of S. aureus (13.4%). 17 Among blood isolates from patients with fistulas or grafts, 55% were S. aureus vs 57% for data pooled from other studies. 16 Compared with data monitoring in the inpatient hospital setting, data monitoring in the outpatient hemodialysis setting is more difficult because fewer diagnostic tests are performed, clinical evaluation and documentation are less detailed, and trained infection control practitioners are usually not avail able. To cope with these challenges, a system was created with the following unique features: simpli fied data collection methods; a carefully defined method for finding infections; a record of the pres ence or absence of criteria for infections, not the infections themselves (ie, the data collector does not have to memorize case definitions); and a com puter algorithm to determine whether the infection case definitions are met. These features are intend ed to increase the accuracy and consistency of data collection at a large number of geographically dis persed facilities.
This data collection system has both strengths and weaknesses. Weaknesses include that the system has not been validated and does not require that data be collected by trained infection control practitioners. In traditional systems, the data collector reports only those events meeting a case definition. In this study's system, a form is completed for each hospitalization or start of IV antimicrobial treatment of any cause, only some of which represent an infection of inter est. This increases the workload but provides a defined method for finding infections and allows cal culation of rates of hospitalization and IV antimicro bial treatments. Another potential problem with this system is that infections treated with oral antimicro bials alone are not counted; thus, only the more seri ous infections are included in our system, and some centers that tend to use oral antimicrobials in prefer ence to IV agents, even occasionally for bacteremia, may have falsely low rates. Conversely, some infec tions may be counted more than once (eg, a patient initially treated with outpatient IV antimicrobial and admitted to a hospital a few days later for the same problem). This "double counting" may lead to a mod est overestimate of infection rates, but the overestiReferences mate should be similar for all centers, and, thus, the relative ranking of the centers should be correct for benchmarking purposes. To some degree, the factors leading to over-vs-under counting of infections may offset each other. However, these potential disadvan tages are compensated for by the simplicity and prac ticality of the system.
As with any voluntary data collection effort, it is uncertain whether the data collected by participat ing centers are representative of other US facilities. Compared with nonparticipating centers, our par ticipating centers were much more likely to be located in hospitals and operated on a nonprofit basis. Additionally, they reported slightly higher use of vancomycin in December 1999; because use of vancomycin can be used as a rough estimate of the number of patients with access infections, our par ticipating centers may have had slightly higher rates of access infections than other US centers.
After adjusting for potential differences in vascular access types, marked differences were noted in the risk of vascular access infections among the partic ipating dialysis centers. By feeding this information back to dialysis center personnel on a routine basis, either through quarterly mailed reports or real-time analyses produced by our Internet-based system, we hope to facilitate improvements in the quality of care at individual units. By comparing practices at centers with high vs low infection rates, we hope to develop new infection control strategies. Dialysis centers wishing to enroll in or receive a protocol for this project may do so by visiting http://www.cdc. gov/ncidod/hip/Dialysis/procedure.htm or by calling the CDC at (404) 498-1109.
